Bioconversion method for anti-AIDS-medicine-reyataz midbody

A biotransformation and anti-AIDS technology, applied in the field of medicine and biology, can solve the problems of too many yeast cells, low enzyme activity, and a large proportion of NAD cost.
CN109943577AActive Publication Date: 2019-06-28NANJING NUOYUN BIOLOGICAL TECH CO LTD
8 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
NANJING NUOYUN BIOLOGICAL TECH CO LTD
Publication Date
2019-06-28

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a bioconversion method for anti-AIDS-medicine-reyataz midbody, and belongs to the technical field of medical biology. Secondary structures of genes and codon usage biases are adjusted, the length of primers is controlled within 60 base, the primers are obtained, the obtained primers are dissolved with double distilled water, then the dissolved primers are added into a reaction system, a prepared PCR reaction system is amplified, obtained DNA fragments are subjected to gel cutting purification, and then are cloned into NdeI / XhoI loci of pET30a with a homologous recombination method, a successfully-sequenced DNA sequence is SEQ ID NO.3, and is named as Sst-2, and the corresponding amino acid sequence of the Sst-2 is SEQ ID NO.4. The bioconversion method is mild in reaction condition, and has the low requirement for equipment, the high temperature or cooling is not required in the production process, energy consumption is low, purification is convenient, single enzyme catalysis is used in the whole system, the cycle number of coenzyme is high, and the reaction condition is mild.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a preparation method of an atazanavir intermediate, in particular to a biotransformation method of an anti-AIDS drug atazanavir intermediate, belonging to the field of medical biotechnology. Background technique

[0002] Atazanavir, sold under the trade name Reyataz, is an antiretroviral drug used for the treatment and prevention of HIV / AIDS. It is currently one of the main anti-AIDS drugs in the world. On the list, it is the most important drug needed by the basic health system. Bristol-Myers Squibb first developed atazanavir, which was publicly introduced in Chinese patent CN10282508C. The US FDA approved it for marketing in 2003, and China also in 2007 Approved for its listing.

[0003] (2R,3S)-1-Chloro-3-tert-butoxycarbonylamino-4-phenyl-2-butanol is used as a key intermediate for the preparation of atazanavir. At present, the main production processes include chemical synthesis and biosynthesis There are two methods, and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More